Bristol Myers Squibb
Ben leads clinical development for Bristol-Myers Squibb’s lung fibrosis pipeline. He is responsible for providing clinical insights into the development strategy and overseeing global clinical trials for assets across all stages of development for fibrotic diseases of the lung and liver. Ben has held this role since late 2016. Ben joined BMS in 2014 as a Study Director, leading global clinical trials for late stage and marketed assets in the Immunoscience pipeline. In this role he also worked with teams advancing early Immunoscience assets to ensure a smooth transition into late stage clinical development, and organized a series of educational sessions for R&D colleagues to facilitate learning and knowledge sharing across functions.